Média

AMAG PHARMACEUTICALS ET NORGINE B.V. CONCLUENT UN ACCORD DE LICENCE EXCLUSIVE POUR COMMERCIALISER CIRAPARANTAG EN EUROPE, AUSTRALIE ET NOUVELLE- ZÉLANDE
08 Septembre 2020

NORGINE A FAIT L’ACQUISITION DU LABORATOIRE AZANTA, RENFORÇANT SA POSITION DE LABORATOIRE PHARMACEUTIQUE LEADER EUROPEEN
19 Mai 2020

Voir plus

What makes us different?

What make Norgine different

 
  • Agile and adaptable infrastructure to win and bring new product opportunities to markets in Europe
  • Strong partnering track record
  • One Norgine approach – think globally, act locally
  • Single integrated business with a direct presence in all major European markets and coverage of the entire market
  • Balanced business with no over-reliance on any single country
  • Solid foundation for the launch of new late stage products
  • Demonstrated manufacturing, clinical development, medical, pharmacovigilance, regulatory, market access and sales & marketing expertise across Europe
  • Private company – celebrated its centenary in 2006

 

The development of innovative new products for the future  is key for Norgine.
We have a long-standing expertise in developing products and also look to acquire research programmes from partners in Europe, the US and elsewhere who have complementary skills and a shared vision for improving healthcare.
Our efforts are focused on unmet needs in disease areas where we believe our skills and experience can make the most difference: gastroenterology, hepatology, critical and supportive care.

 

Capabilities

We have the core capabilities and skills to foster innovation and translate opportunities into proven advances for patients.

 

Norgine strong in-house development team combines the expertise of clinical, regulatory, pharmacovigilance, medical affairs, scientific publications functions with a ‘virtual’ network model for pre-clinical development.

 

Norgine Development Centre is located in Hengoed Wales.